Acrivon Therapeutics, Inc. Common Stock (ACRV) 10-Year Financial Performance & Capital Metrics

ACRV • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutAcrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.Show more

Revenue $0
EBITDA -$88M -32.2%
Net Income -$81M -33.4%
EPS (Diluted) -2.10 +23.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -54.07% -30.6%
ROIC -58.06% -35.7%
Debt/Equity 0.02 -46.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.4x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 73.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-6.2%

EPS CAGR

10Y-

5Y-

3Y-

TTM21.11%

ROCE

10Y Avg-71.85%

5Y Avg-71.85%

3Y Avg-42.32%

Latest-58.62%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	13K	0	0	536K	1.01M
COGS % of Revenue	-	-	-	-	-
Gross Profit+	-13K	0	0	-536K	-1.01M
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	1%	-	-	-0.88%
Operating Expenses+	3.17M	16.18M	32.66M	66.7M	88.19M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	1.3M	2.47M	8.71M	21.21M	25.21M
SG&A % of Revenue	-	-	-	-	-
Research & Development	1.87M	13.72M	23.95M	45.49M	63.99M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	0	0	-1.01M
Operating Income+	-3.17M	-16.18M	-32.66M	-67.24M	-89.2M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-4.11%	-1.02%	-1.06%	-0.33%
EBITDA+	-3.15M	-16.15M	-32.29M	-66.7M	-88.19M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-4.12%	-1%	-1.07%	-0.32%
D&A (Non-Cash Add-back)	13K	37K	364K	536K	1.01M
EBIT	-5.31M	-16.18M	-32.66M	-60.39M	-80.56M
Net Interest Income+	0	0	0	0	9.2M
Interest Income	0	0	0	0	9.2M
Interest Expense	0	0	0	0	0
Other Income/Expense	-2.14M	-59K	1.49M	6.85M	8.64M
Pretax Income+	-5.31M	-16.24M	-31.17M	-60.39M	-80.56M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-5.31M	-16.24M	-31.17M	-60.39M	-80.56M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-2.06%	-0.92%	-0.94%	-0.33%
Net Income (Continuing)	-5.31M	-16.24M	-31.17M	-60.39M	-80.56M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.41	-1.26	-1.42	-2.74	-2.10
EPS Growth %	-	-2.07%	-0.13%	-0.93%	0.23%
EPS (Basic)	-0.41	-1.26	-1.42	-2.74	-2.10
Diluted Shares Outstanding	12.91M	12.91M	21.92M	22.08M	38.3M
Basic Shares Outstanding	12.91M	12.91M	21.92M	22.08M	38.3M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.72M	100.41M	132.09M	129.69M	181.63M
Cash & Short-Term Investments	1.58M	99.6M	127.75M	127.46M	179.48M
Cash Only	1.58M	99.6M	29.52M	36.02M	39.82M
Short-Term Investments	0	0	98.23M	91.44M	139.66M
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	0	4.34M	2.23M	2.15M
Total Non-Current Assets+	466K	6.18M	49.13M	8.57M	14.96M
Property, Plant & Equipment	59K	5.79M	6.86M	7.91M	8.03M
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	41.88M	0	5.09M
Other Non-Current Assets	407K	388K	388K	665K	1.84M
Total Assets+	2.19M	106.59M	181.23M	138.26M	196.59M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	47.78%	0.7%	-0.24%	0.42%
Total Current Liabilities+	613K	2.91M	6.52M	13.3M	17.21M
Accounts Payable	136K	964K	904K	5.05M	758K
Days Payables Outstanding	3.82K	-	-	3.44K	275.02
Short-Term Debt	58K	0	0	0	1.06M
Deferred Revenue (Current)	0	66K	69K	0	0
Other Current Liabilities	334K	667K	2.66M	3.86M	5.46M
Current Ratio	2.80x	34.46x	20.27x	9.75x	10.55x
Quick Ratio	2.80x	34.46x	20.27x	9.75x	10.55x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	9.98M	127.48M	4.24M	3.77M	2.59M
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	4.96M	4.24M	3.77M	2.59M
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	9.98M	122.52M	0	0	0
Total Liabilities	10.6M	130.4M	10.75M	17.07M	19.8M
Total Debt+	58K	5.63M	4.96M	4.64M	3.65M
Net Debt	-1.52M	-93.97M	-24.56M	-31.37M	-36.17M
Debt / Equity	-	-	0.03x	0.04x	0.02x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-	-	-	-
Total Equity+	-8.41M	-23.81M	170.47M	121.19M	176.79M
Equity Growth %	-	-1.83%	8.16%	-0.29%	0.46%
Book Value per Share	-0.65	-1.84	7.78	5.49	4.62
Total Shareholders' Equity	-8.41M	-23.81M	170.47M	121.19M	176.79M
Common Stock	1K	2K	22K	23K	31K
Retained Earnings	-8.62M	-24.86M	-56.03M	-116.42M	-196.98M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	-95K	-83K	447K
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.8M	-13.98M	-30.12M	-42.64M	-65.67M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-3.99%	-1.15%	-0.42%	-0.54%
Net Income	-5.31M	-16.24M	-31.17M	-60.39M	-80.56M
Depreciation & Amortization	13K	37K	364K	536K	1.01M
Stock-Based Compensation	3K	497K	2.19M	11.62M	14.29M
Deferred Taxes	0	0	0	-3.61M	0
Other Non-Cash Items	2.17M	1.4M	33K	1.06M	-2.85M
Working Capital Changes	317K	328K	-1.53M	8.14M	2.44M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	81K	798K	-245K	3.61M	-3.59M
Cash from Investing+	-15K	-238K	-141.68M	50.72M	-51.77M
Capital Expenditures	-15K	-238K	-2.17M	-1.29M	-2.77M
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	2.89M	112.22M	101.71M	-1.55M	121.03M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	1K	-2.75M	-1.3M	51.03M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-2.82M	-14.22M	-32.28M	-43.93M	-68.44M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-4.05%	-1.27%	-0.36%	-0.56%
FCF per Share	-0.22	-1.10	-1.47	-1.99	-1.79
FCF Conversion (FCF/Net Income)	0.53x	0.86x	0.97x	0.71x	0.82x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-42.5%	-41.41%	-54.07%
Return on Invested Capital (ROIC)	-	-	-174.12%	-42.78%	-58.06%
Debt / Equity	-	-	0.03x	0.04x	0.02x
FCF Conversion	0.53x	0.86x	0.97x	0.71x	0.82x

Frequently Asked Questions

Growth & Financials

Acrivon Therapeutics, Inc. Common Stock (ACRV) grew revenue by 0.0% over the past year. Growth has been modest.

Acrivon Therapeutics, Inc. Common Stock (ACRV) reported a net loss of $81.8M for fiscal year 2024.

Dividend & Returns

Acrivon Therapeutics, Inc. Common Stock (ACRV) has a return on equity (ROE) of -54.1%. Negative ROE indicates the company is unprofitable.

Acrivon Therapeutics, Inc. Common Stock (ACRV) had negative free cash flow of $68.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener